Baker Bros. Advisors HOOK Position
ExitedBaker Bros. Advisors exited their position in HOOKIPA Pharma Inc. (HOOK) in Q3 2025, after holding the stock for 11 quarters.
The position was first reported in Q1 2023 and has been tracked across 11 quarterly 13F filings.
2 other tracked funds also hold HOOK.
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Full company profile →Short Interest
0.5%
0.6 days to cover
Baker Bros. Advisors HOOK Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -812,814 | $0 |
| Q2 2025 | Held | 812,814 | — | $1.0M |
| Q1 2025 | Held | 812,814 | — | $878K |
| Q4 2024 | Held | 812,814 | — | $1.6M |
| Q3 2024 | Decreased | 812,814 | -7,315,337 | $3.5M |
| Q2 2024 | Held | 8,128,151 | — | $4.8M |
| Q1 2024 | Held | 8,128,151 | — | $5.8M |
| Q4 2023 | Increased | 8,128,151 | +62,753 | $6.6M |
| Q3 2023 | Increased | 8,065,398 | +3,639,863 | $5.0M |
| Q2 2023 | Increased | 4,425,535 | +950,000 | $3.9M |
| Q1 2023 | New | 3,475,535 | +3,475,535 | $2.6M |
Frequently Asked Questions
Does Baker Bros. Advisors own HOOK?
No. Baker Bros. Advisors exited their position in HOOKIPA Pharma Inc. (HOOK) in Q3 2025. They previously held the stock for 11 quarters.
How many hedge funds own HOOK?
2 specialist biotech hedge funds currently hold HOOK, including EcoR1 Capital, Redmile Group. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy HOOK?
Baker Bros. Advisors's position in HOOK was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's HOOK position increasing or decreasing?
Baker Bros. Advisors completely exited their HOOK position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
HOOKCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →